• Sarepta Therapeutics, Inc. (NASDAQ:SRPT) experiences a significant stock price drop following a patient death related to its ELEVIDYS treatment, but long-term investors might see this as an opportunity.
• The company's overall product revenue has seen a 70% growth, indicating underlying business strength despite recent setbacks.
• With a current market capitalization of approximately $1.96 billion and a trading volume of 30,136,821 shares, SRPT's valuation suggests it may be deeply oversold.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotechnology company focused on developing precision genetic medicines to treat rare diseases. The company is known for its work in the field of Duchenne muscular dystrophy (DMD) and other neuromuscular diseases. Sarepta's competitors include companies like Pfizer and Roche, which are also involved in developing treatments for similar conditions.

On June 15, 2025, Kostas Biliouris from BMO Capital set a price target of $70 for SRPT. At that time, the stock was priced at $36.18, suggesting a potential increase of about 93.48% to reach the target. However, recent events have significantly impacted the stock's performance. The stock has plunged over 47% following the second patient death related to its ELEVIDYS treatment, raising serious safety concerns and leading to the suspension of trials.

Despite these setbacks, Sarepta's current valuation is considered deeply oversold. The stock is now priced at $19.91, reflecting a decrease of 44.97% with a change of $16.27. For long-term investors, this may present an opportunity to invest at these lower levels. Although ELEVIDYS revenue has decreased sequentially, it still shows a remarkable 180% increase year-over-year, indicating potential for recovery.

Sarepta's overall product revenue has grown by 70%, showcasing the underlying strength of the business despite recent challenges. The company's market capitalization stands at approximately $1.96 billion, with a trading volume of 30,136,821 shares for the day. The stock has fluctuated between a low of $18.30 and a high of $21.55 today, with a 52-week high of $173.25 and a low of $18.30.